Dr. John Orloff
- r
- D
- i
Appointment to the Board
April 2022, previously on the Board of Directors of BenevolentAI Ltd since September 2021.
Experience and expertise
John was executive vice president and global head of research & development at Alexion where his leadership in expanding the development pipeline from 3 to 30 programmes supported the recent $39 billion acquisition of Alexion by AstraZeneca. Prior to Alexion, John was global head of R&D and chief scientific officer at Baxalta, and has also held executive leadership roles with Novelion, Baxter International, Merck Serono, Novartis and Merck Research Laboratories.
Before entering the biopharmaceutical industry, John was a faculty member at the Yale University School of Medicine. He holds an undergraduate degree in Chemistry from Dartmouth College and earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in Endocrinology and Metabolism at Yale University School of Medicine.
Current external appointments
John is a venture partner at Agent Capital and is a non-executive director of Zenas BioPharma.